Corcept Therapeutics (CORT) Stock Forecast & Price Target

Corcept Therapeutics is projected to achieve robust sales growth for its product Korlym, with anticipated annual revenue between $800 million and $850 million in FY2025, representing a year-over-year increase of 19% to 26%. This positive outlook is further supported by a more than 40% increase in volume over the past two quarters, indicating strong underlying demand despite recent commercial challenges. Additionally, early data from clinical trials involving relacorilant suggest significant therapeutic benefits and position the company well for potential regulatory approvals, which could broaden its market opportunities in the coming years.

Corcept Therapeutics's stock faces significant downward pressure due to a recent complete response letter (CRL) from the FDA, delaying the launch of relacorilant for treating Cushing's Syndrome, which has resulted in a drastic reduction of the 12-month price target from $145 to $90 per diluted share. Additionally, the company's stock experienced a notable decline, closing at approximately $35, representing a loss of 50.4%, highlighting heightened market uncertainty regarding the commercial prospects of Korlym and potential weaknesses in revenue reporting expected in Q3 2025. Financial analyses projecting future revenues and earnings also indicate substantial risks inherent in the company's valuation, as they are heavily reliant on market performance metrics that are presently volatile and subject to regulatory scrutiny.